₹5.15
−0.96%NSE close, 16 Nov 2026
−48.76%
Vivimed Labs is a small cap company, listed on NSE under the symbol VIVIMEDLAB. At ₹5.15 a share, the market values the whole company at ₹43 crore.
In FY26, it reported sales of ₹70 crore and a net loss of ₹175 crore, an operating margin of -216.2%. Over the last three years, sales fell 27.9% a year.
Promoters hold 7.57% of the shares, and have pledged 15.2% of their holding. Foreign institutions hold 1.64%, and domestic institutions, mutual funds among them, 0.00%.
₹ crore. Consolidated figures.
The Exchange has sought clarification from Vivimed Labs Limited for the quarter ended 31-Mar-2026 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following:…
The financial results for the period ended March 31, 2026.
COC meeting
| Jun 2025 |
|---|
| Sep 2025 |
|---|
| Dec 2025 |
|---|
| Mar 2026 |
|---|
| Sales | 35.4 | 33.6 | 41.5 | 38.6 | 29.4 | 24.8 | 36.5 | 25.6 | 21.4 | 20.6 | 16.0 | 12.0 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Expenses | 35.7 | 39.5 | 40.2 | 67.1 | 33.3 | 25.4 | 35.4 | 27.6 | 21.7 | 21.6 | 26.9 | 151 |
| Operating profit | −0.3 | −5.9 | 1.3 | −28.5 | −3.9 | −0.6 | 1.1 | −2.0 | −0.3 | −1.0 | −10.9 | −139 |
| Operating margin | -0.9% | -17.5% | 3.1% | -73.7% | -13.4% | -2.6% | 2.9% | -7.8% | -1.3% | -4.6% | -68.3% | -1,159.9% |
| Other income | 0.1 | 2.2 | 0.0 | 7.6 | 0.1 | 0.0 | 0.1 | 4.2 | 0.4 | 0.2 | 0 | 5.8 |
| Interest | 10.7 | 11.9 | 13.2 | −33.3 | 0.3 | 0.4 | 0.5 | 1.7 | 0.6 | 1.7 | 1.0 | 1.0 |
| Depreciation | 4.7 | 4.7 | 4.7 | 5.8 | 4.0 | 4.1 | 6.6 | 5.5 | 5.0 | 4.9 | 4.6 | 11.5 |
| Profit before tax | −15.6 | −20.3 | −16.6 | 6.7 | −8.2 | −5.1 | −6.0 | −5.0 | −5.5 | −7.3 | −16.6 | −146 |
| Tax | 0 | 0 | −0.6 | 1.4 | 0 | 0 | 0 | 0.1 | 0 | 0 | 0 | 0.1 |
| Net profit | – | −20.3 | −16.1 | 5.3 | −8.2 | −5.1 | −6.0 | −5.1 | −5.5 | −7.3 | −16.6 | −146 |
| EPS (₹) | – | -2.45 | -1.24 | 0.64 | -0.99 | -0.60 | -0.72 | -0.67 | -0.66 | -0.88 | -0.88 | -17.74 |
₹ crore, financial years to March.
| Line | FY19 S | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|---|---|
| Sales | 252 | 1,059 | 861 | 237 | 187 | 149 | 116 | 70.0 |
| Expenses | 185 | 1,051 | 838 | 245 | 374 | 183 | 129 | 221 |
| Operating profit | 67.3 | 8.1 | 23.8 | −8.1 | −187 | −33.4 | −12.6 | −151 |
| Operating margin | 26.7% | 0.8% | 2.8% | -3.4% | -100.1% | -22.4% | -10.8% | -216.2% |
| Other income | 8.5 | 8.3 | 9.8 | 1.3 | 1.0 | 10.0 | 4.4 | 6.3 |
| Interest | 52.4 | 58.9 | 53.9 | 39.8 | 35.9 | 2.4 | 3.0 | 4.2 |
| Depreciation | 18.3 | 67.0 | 55.5 | 18.3 | 108 | 19.9 | 20.2 | 26.1 |
| Profit before tax | 5.1 | −109 | −75.8 | −64.8 | −331 | −45.8 | −31.4 | −175 |
| Tax | −1.1 | −0.4 | 2.0 | 2.8 | −2.1 | 0.8 | 0.1 | 0.1 |
| Net profit | 6.2 | −109 | −77.8 | −67.7 | −328 | −46.7 | −31.5 | −175 |
| EPS (₹) | 0.75 | -13.16 | -18.76 | -8.16 | -37.64 | -1.17 | -3.85 | -21.15 |
₹ crore, at each year's end and the latest half year.
₹ crore, by financial year, and the latest half year.
Margins, returns, debt, tax and cash.
| Line | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|---|---|
| Net margin | 2.5% | -10.3% | -9.0% | -28.5% | -175.3% | -31.3% | -27.1% | -250.6% |
| Operating margin | 26.7% | 0.8% | 2.8% | -3.4% | -100.1% | -22.4% | -10.8% | -216.2% |
| Return on equity | – | – | – | – | -832.0% | – | – | – |
| Return on capital employed | – | – | – | – | -70.5% | – | – | – |
| Return on assets | – | – | – | – | -33.2% | -4.9% | -3.4% | -23.3% |
| Debt to equity | – | – | – | – | 9.60 | – | – | – |
| Interest coverage | 1.10 | -0.90 | -0.40 | -0.60 | -8.20 | -17.90 | -9.60 | -41.00 |
| Debt to assets | – | – | – | – | 0.38 | 0.40 | 0.92 | 0.53 |
| Current ratio | – | – | – | – | 0.78 | 0.83 | 0.80 | 0.37 |
| Quick ratio | – | – | – | – | 0.60 | 0.68 | 0.66 | 0.35 |
| Cash ratio | – | – | – | – | 0.01 | 0.00 | 0.00 | 0.00 |
| Asset turnover | – | – | – | – | 0.19 | 0.16 | 0.13 | 0.09 |
| Fixed asset turnover | – | – | – | – | 0.67 | 0.57 | 0.46 | 0.30 |
| Inventory turnover | – | – | – | – | – | 1.10 | 1.00 | 5.80 |
| Receivables turnover | – | – | – | – | 2.40 | 1.80 | 1.60 | 1.50 |
| Gross margin | – | – | – | – | – | 52.1% | 48.5% | -5.4% |
The Exchange has sought clarification from Vivimed Labs Limited for the quarter ended 31-Dec-2025 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following:…
Re lodgment
The Exchange had sought clarification from Vivimed Labs Limited for the quarter ended 31-Mar-2025 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company was required to clarify the…
A copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.